Bayer committed to transparency: Posts more than 300 glyphosate safety study summaries online

Bayer to drive value creation as company pursues ambitious growth targets through 2022

Company strongly positioned to benefit from key megatrends / ...

FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD

The software in development intends to support clinical decision-making of chronic thromboembolic pulmonary hypertension – a progressive and life-threatening condition ...

Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability

Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability

Group plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl’s™, and sell its 60-percent interest in Currenta, a site services provider in Germany ...

Bayer receives EU approval for its hemophilia A treatment Jivi®

The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies ...

U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion

First treatment with a tumor-agnostic indication at the time of initial FDA approval / Larotrectinib approved under the brand name Vitrakvi® ...

Bayer to offer access to its owned glyphosate studies

Intacta RR2-PRO™-soybeans lead to positive environmental impacts in South America

Transparency Initiative by Bayer wins Best Public Outreach Program at Agrow Awards 2018